Lumira Capital leads new funding of drug developer AvidBiologics
AvidBiologics Inc, a Toronto-based oncology drug development startup, has secured follow-on financing of an undisclosed amount. The round was led by Canadian life sciences-focused venture capital firm Lumira Capital, with participation from the MaRS Investment Accelerator Fund, MaRS Innovation, Rosseau Asset Management and the company's founding investors. A 2011 spin-out from YM BioSciences Inc, and founded on antibody-drug conjugate technologies developed in partnership with the National Research of Council Canada, AvidBiologics plans to use funding proceeds for clinical trials.
29 September 2014•4 mins read
